查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球呼吸系统疾病治疗市场 - 2022-2029
市场调查报告书
商品编码
1176600

全球呼吸系统疾病治疗市场 - 2022-2029

Global Breathing Disorder Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

呼吸系统药物是用于治疗某些呼吸道或呼吸系统疾病（例如慢性阻塞性肺病和哮喘）的药物。 这些药物可减轻炎症并打开呼吸道，使呼吸更顺畅。 更多地暴露在空气污染和灰尘中，以及吸烟的增加将推动这些药物的采用。

市场动态

呼吸系统疾病药物市场受到哮喘和慢性阻塞性肺病等呼吸系统疾病患者人数增加、先进技术的兴起、研发投资增加以及新兴市场医疗基础设施投资增加的推动。I在这里。

呼吸系统疾病治疗药物渗透率的提高和研发投资的增加预计将推动市场的增长。

呼吸系统疾病药物市场受到技术进步、呼吸系统疾病治疗需求增加、研发投资激增、慢性呼吸系统疾病（如哮喘、慢性阻塞性肺病、慢性支气管炎）增加以及新兴国家医疗基础设施的推动。它被驱动通过医学的进步和使用最新技术改进新药。 据世界卫生组织称，慢性阻塞性肺病 (COPD) 影响着全世界近 2 亿人。 目前，政府增加用于治疗慢性病的资金正在推动市场的增长。 例如，在欧盟，慢性阻塞性肺病的直接成本约占医疗保健总成本的 6%，占呼吸系统疾病总成本的近 56%。

技术进步正在增加呼吸系统疾病药物的采用。 呼吸系统疾病的增加、对治疗呼吸系统疾病的支气管扩张剂和抗生素的认识提高以及政府和私营公司增加医疗保健支出可能会导致基础设施投资增加，从而推动呼吸系统疾病治疗市场。

各种新产品的发布和研究正在为市场的增长做出贡献。 例如，2022 年 3 月 14 日，诺华旗下的 Sandoz 宣布已成功收购总部位于英国的药物输送和医疗器械开发商 Coalesce Product Development Limited。 通过此次收购，Sandoz 获得了重要的 Coalesse 能力，以帮助建立其现有的呼吸产品组合。

与呼吸系统疾病药物相关的副作用预计会阻碍市场增长。

全球呼吸系统疾病药物市场因呼吸系统疾病治疗的副作用而受阻。 副作用包括口干、发抖、头晕、喉咙痛或喉咙发痒、流鼻涕和胃部不适。

关于批准用于治疗呼吸系统疾病和支气管扩张剂相关震颤、神经紧张、心悸和肌肉痉挛等不良事件的药物的严格规章制度阻碍了市场增长。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了积极影响。 COVID-19 的爆发严重影响了医疗保健行业。 由于各种研究，随着 COVID 病例数量的增加，临床试验已经认真开始，因此 COVID 导致呼吸系统疾病治疗市场取得了巨大收益。 主要製造商已经启动了各种研究和临床试验。 全球正在发生多项举措、产品发布、合作和合併，推动了市场的增长。 例如，2021 年 12 月 17 日，安进公司宣布阿斯利康和安进公司的 Tezspire（tezepelumab-ekko）获得美国食品药品监督管理局（FDA）的批准，用于 12 岁儿童和成人严重哮喘患者的附加维持治疗和更老。宣布它是

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 呼吸系统疾病药物流行率增加
      • 研发费用增加
      • 技术进步的增加
    • 约束因素
      • 与呼吸系统疾病药物相关的副作用
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章药物类别

  • 抗菌剂
    • 妥布霉素 (TOBI)
    • 喷他□ (nevpent)
    • 利巴韦林（病毒唑）
  • 肾上腺皮质类固醇
    • 布地奈德
    • 外消旋肾上腺素
  • 支气管扩张剂
    • 间丙肾上腺素（Alpent）
    • 异丙托铵 (Atrovent)
    • 福莫特罗（表演者）
    • 阿福莫特罗（Brovana）
    • 盐酸左沙丁胺醇 (Zopenex)
    • 硫酸沙丁胺醇 (Acuneb)
  • 抗组胺剂
    • 扎鲁司特
    • 齐拉顿
    • 孟鲁司特
  • 呼吸兴奋剂
    • 西替利秦
    • 氯雷他定
  • 其他

第八章按功效与作用

  • 慢性阻塞性肺疾病 (COPD)
  • 支气管哮喘
  • 囊性纤维化
  • 肺动脉高压
  • 肺癌
  • 过敏性鼻炎
  • 特发性肺纤维化
  • 其他

第 9 章（按销售渠道）

  • 医院药房
  • 零售药房
  • 在线药店

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第12章公司简介

  • F. Hoffmann-La Roche
    • 公司概况
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • AstraZeneca
  • GSK plc
  • Abbott Laboratories
  • Amgen Inc.
  • Novartis AG
  • Medtronic plc
  • Dr. Reddy's Laboratories Ltd.
  • Bayer AG
  • Biogen

第13章 DataM

简介目录
Product Code: DMPH4725

Market Overview

Breathing disorder drugs are medications used for treating several respiratory or breathing disorders, such as COPD and asthma. These medicines make breathing easier by reducing inflammation and opening the airways. High exposure to air pollution and dust and increased smoking will enhance the adoption of these drugs.

Market Dynamics

The market for breathing disorder treatment is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments and the rising investment in healthcare infrastructure in emerging markets.

The rising adoption of breathing disorders drugs and increasing investment in research and development are expected to drive the market's growth.

The breathing disorder treatment market is driven by rising advancements in technology, an increase in demand for breathing disorder drugs, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost the market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.

Technological advances have resulted in increasing breathing disorder drugs adoption. The rising number of respiratory disorders, increasing awareness about bronchodilators and antimicrobial drugs for treating respiratory disorders and rising healthcare expenditure by governments and the private sector could lead to higher infrastructure investments and drive the breathing disorder treatment market.

Various novel product launches and research studies contribute to the market's growth. For instance, in March 14, 2022, Sandoz, a Novartis subsidiary, announced its successful acquisition of Coalesce Product Development Limited, a UK-based drug delivery and medical device development company. Sandoz, with this acquisition, acquired the significant capabilities of Coalesce that can help in building on its existing respiratory medicines portfolio.

The side effects associated with breathing disorder treatment drugs are expected to hamper the market's growth.

The global market for breathing disorder treatment is restrained by the side effects of drugs for breathing disorder treatment. Side effects include dry mouth, tremors, dizziness, irritated or scratchy throat, runny nose and upset stomach.

Stringent rules and regulations for respiratory disorders treatment drugs approval and adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The breathing disorder treatment market has experienced huge profits due to COVID as various research, and clinical trials got started in full swing due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in December 17, 2021, Amgen announced that AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.

Segment Analysis

The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The bronchodilators segment is the highest market holder in the global breathing disorder treatment market. The global breathing disorder treatment market is segmented on the basis of drug class in antimicrobial, corticosteroid, bronchodilator, antihistamines, respiratory stimulants and others. The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.

These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs basically stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), who experienced asthma exacerbations.

Geographical Analysis

North America holds the largest market share in the global breathing disorder treatment market.

North America dominates the global breathing disorder treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults suffered from chronic obstructive pulmonary disease (COPD) in the United States in 2020. And 25 million have asthma.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of medications for breathing disorder treatment in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the breathing disorder treatment market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in March 23, 2020, Bayer announced its license agreement and research collaboration with Curadev, a domestic drug discovery firm for discovering novel drug candidates for cardiovascular, lung and inflammatory diseases treatment.

Competitive Landscape

The breathing disorder treatment market is highly competitive with local and global companies' presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Abbott Laboratories, Amgen Inc., Novartis AG, Medtronic plc, Dr. Reddy's Laboratories Ltd., Bayer AG, Biogen and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in February 16, 2022, Mankind Pharma announced that it had signed an acquisition agreement with Dr. Reddy's Laboratories for two brands, Daffy and Combihale. Combihale is utilized for treating chronic obstructive pulmonary disease and asthma.

Novartis AG.

Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Arcapta Neohaler: Arcapta Neohaler is the once-daily, 24-hour long-acting beta2-agonist that has been approved for airflow obstruction in COPD patients' maintenance treatment.

Key Development: In November 19, 2020, Novartis announced its exclusive global collaboration and license agreement with Mesoblast for the development, manufacturing and selling of remestemcel-L for acute respiratory distress syndrome (ARDS) treatment, including that associated with COVID-19.

The global breathing disorder treatment market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising adoption of breathing disorder drugs
      • 4.1.1.2. Increasing research and development expenditure
      • 4.1.1.3. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the breathing disorder treatment drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Antimicrobial *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Tobramycin (TOBI)
    • 7.2.4. Pentamidine (Nebupent)
    • 7.2.5. Ribavirin (Virazole)
  • 7.3. Corticosteroid
    • 7.3.1. Budesonide
    • 7.3.2. Racemic epinephrine
  • 7.4. Bronchodilator
    • 7.4.1. Metaproterenol (Alupent)
    • 7.4.2. Ipratropium (Atrovent)
    • 7.4.3. Formoterol (Perforomist)
    • 7.4.4. Arformoterol (Brovana)
    • 7.4.5. Levalbuterol HCl (Xopenex)
    • 7.4.6. Albuterol sulfate (AccuNeb)
  • 7.5. Antihistamines
    • 7.5.1. Zafirlukast
    • 7.5.2. Zileuton
    • 7.5.3. Montelukast
  • 7.6. Respiratory stimulants
    • 7.6.1. Cetirizine
    • 7.6.2. Loratidine
  • 7.7. Others

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Chronic Obstructive Pulmonary Disease (COPD) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Asthma
  • 8.4. Cystic Fibrosis
  • 8.5. Pulmonary Hypertension
  • 8.6. Lung Cancer
  • 8.7. Allergic Rhinitis
  • 8.8. Idiopathic Pulmonary Fibrosis
  • 8.9. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca
  • 12.3. GSK plc
  • 12.4. Abbott Laboratories
  • 12.5. Amgen Inc.
  • 12.6. Novartis AG
  • 12.7. Medtronic plc
  • 12.8. Dr. Reddy's Laboratories Ltd.
  • 12.9. Bayer AG
  • 12.10. Biogen

LIST NOT EXHAUSTIVE

13. Global Breathing Disorder Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Indication
  • 13.3. Contact Us